Solution designed to accelerate the process of matching patients with eligible clinical trials.
Belong.Life has officially launched Tara, a SaaS-based conversational AI cancer clinical trial matching platform for health providers and contract research organizations (CROs). According to the company, Tara is designed to accelerate the process of matching patients with eligible clinical trials, enabling increased recruitment at significantly lower costs. Following the launch of Dave, Tara is Belong’s second AI Health Mentor suite of solutions.
"Since our founding, Belong has provided clinical trial matching services to more than 30,000 patients," said Eliran Malki, CEO, co-founder, Belong.Life, in a company press release. "Tara is a natural extension of our services, helping to optimize clinical trial matching to benefit stakeholders with increased patient recruitment, improved randomization, and reduced costs and logistical challenges. Tara will enable more patients around the world to access clinical trials."
Reference: Belong.Life Launches New Conversational AI SaaS Solution for Cancer Clinical Trial Matching and Recruitment. PR Newswire. September 13, 2023. Accessed September 14, 2023. https://www.prnewswire.com/news-releases/belonglife-launches-new-conversational-ai-saas-solution-for-cancer-clinical-trial-matching-and-recruitment-301926197.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.